**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Guoqing Sheng, Alexion, AstraZeneca Rare Disease, Boston, MA, USA

**Main Body of the Abstract**
Background: The current treatment of AL amyloidosis only aims to stop excess free light chain production but lacks therapies to remove amyloid deposits from organs. Anselamimab (CAEL-101) is a monoclonal antibody designed to bind misfolded light chain to promote amyloid fibril removal. The CARES program investigates the safety and efficacy of anselamimab plus standard of care chemotherapy, cyclophosphamide-bortezomib-dexamethasone (CyBorD) ± daratumumab, in patients with European Modification of Mayo 2004 Stage IIIa and IIIb AL.
Methods: Patients with newly-diagnosed AL and advanced cardiac involvement were randomly assigned 2:1 to receive anselamimab or placebo. The primary endpoint is the time to all-cause mortality. Here, we present the baseline demographics and characteristics of participants in the fully enrolled program.
Results: Patients with Mayo stage IIIa (N=281) or IIIb (N=125) were enrolled at 125 sites in 21 countries. In the stage IIIa study (NCT04512235), 70% were male, 73% were Caucasian, and the median age was 66 years. The median NT-proBNP, Troponin T, and dFLC were 3898 ng/L, 79 ng/L, and 299 mg/L, respectively. In the stage IIIb study (NCT04504825), 59% were male, 73% were Caucasian, and the median age was 68 years. The median NT-proBNP, Troponin T, and dFLC were 14685 ng/L, 138 ng/L, and 343 mg/L, respectively.
Conclusions:  With 406 enrolled patients with advanced stage AL amyoidosis, the CARES program includes the largest prospective AL amyloidosis study to date and the first global phase III study in stage IIIb patients. The study is ongoing until the pre-specified number of mortality events is reached.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Guoqing Sheng, Alexion, AstraZeneca Rare Disease, Boston, MA, USA

**Main Body of the Abstract**
**Background:** The current treatment of AL amyloidosis only aims to stop excess free light chain production but lacks therapies to remove amyloid deposits from organs. Anselamimab (CAEL-101) is a monoclonal antibody designed to bind misfolded light chain to promote amyloid fibril removal. The CARES program investigates the safety and efficacy of anselamimab plus standard of care chemotherapy, cyclophosphamide-bortezomib-dexamethasone (CyBorD) ± daratumumab, in patients with European Modification of Mayo 2004 Stage IIIa and IIIb AL.
**Methods:** Patients with newly-diagnosed AL and advanced cardiac involvement were randomly assigned 2:1 to receive anselamimab or placebo. The primary endpoint is the time to all-cause mortality. Here, we present the baseline demographics and characteristics of participants in the fully enrolled program.
**Results:** Patients with Mayo stage IIIa (N=281) or IIIb (N=125) were enrolled at 125 sites in 21 countries. In the stage IIIa study (NCT04512235), 70% were male, 73% were Caucasian, and the median age was 66 years. The median NT-proBNP, Troponin T, and dFLC were 3898 ng/L, 79 ng/L, and 299 mg/L, respectively. In the stage IIIb study (NCT04504825), 59% were male, 73% were Caucasian, and the median age was 68 years. The median NT-proBNP, Troponin T, and dFLC were 14685 ng/L, 138 ng/L, and 343 mg/L, respectively.
**Conclusions:**  With 406 enrolled patients with advanced stage AL amyoidosis, the CARES program includes the largest prospective AL amyloidosis study to date and the first global phase III study in stage IIIb patients. The study is ongoing until the pre-specified number of mortality events is reached.



Demographic and Baseline Characteristics of Participants in Cardiac Amyloid Reaching for Extended Survival (CARES) Trials: Two Randomized, Double-blind, Placebo-controlled, International Phase 3 Trials Assessing the Safety and Efficacy of Anselamimab (CAEL-101) in Patients with European Modification of Mayo 2004 Stage IIIa or Stage IIIb AL Amyloidosis PA156 (#242)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.